▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting
Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting
View More ⏩
Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston
The liver meeting has been fantastic. There’s a…
Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston
Discovers new clinical trials and new biomarkers
View More ⏩
Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.
Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.
View More ⏩
Prof Dufour Discusses Best Practices About the Diagnosis of NASH
Prof Dufour Discusses Best Practices About the Diagnosis of NASH
View More ⏩
Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH
So the diabetologists are recognizing that they have…
Why are PPAR agonists a promising option for the management of NASH ?
Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.
View More ⏩
Lipotoxicity in NASH
That’s a very important concept because lipotoxicity is…
Prof Szabo Discusses the Progresses of the Quest of Biomarkers in NASH
Discover the progresses of the quest for biomarkers in NASH with Prof Szabo
View More ⏩
An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA
Prevalence of NAFLD (non-alcoholic fatty liver disease) affects…
What are the current definitions ? Prof Abdelmalek, USA
So NAFLD (non-alcoholic fatty liver disease) is a…
Learn more about the burden of the disease, Prof Sven Francque, Belgium
June 12 is dedicated to increasing awareness about non-alcoholic steatohepatitis, or NASH, among various populations: the general public, at-risk patients, the medical community, public health authorities, and the media.
View More ⏩
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES